Drugs / ACE393
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00859716 | Oct 2008 → Mar 2009 | campylobacteriosis | TD Vaccines A/S | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00859716 ↗ |
| Modality | Vaccine | “ACE393, a protein sub-unit vaccine” NCT00859716 ↗ |
| Route | Intramuscular | “ACE393 or placebo will be administered twice by intramuscular injection on an outpatient basis, three weeks apart and then the subjects will be challenged three weeks later...” NCT00859716 ↗ |